Overview

POC Study in Partially Responsive Generalized Anxiety Disorder

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
PF-06372865